This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen
by Zacks Equity Research
Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen are included in this Analyst Blog.
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
by Ahan Chakraborty
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
Sage Therapeutics to Reduce Workforce by 33%, Stock Down
by Zacks Equity Research
SAGE announces a portfolio reprioritization plan to focus on the launch of the depression drug Zurzuvae and other pipeline developments. Stock falls in after-hours trading.
Lilly Loses Around $14B This Week: How to Play LLY Stock
by Kinjel Shah
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease
by Zacks Equity Research
Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.
Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
by Zacks Equity Research
The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on the stock.
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
by Zacks Equity Research
Sage Therapeutics announces discontinuation of the collaboration agreement with Biogen related to SAGE-324 for essential tremor.
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
by Zacks Equity Research
Biohaven and Zevra are in the spotlight following positive updates on key candidates.
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
by Zacks Equity Research
The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets the primary endpoint.
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
by Zacks Equity Research
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
by Kinjel Shah
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
Lilly Gets FDA Approval for Eczema Drug Ebglyss
by Zacks Equity Research
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
by Zacks Equity Research
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
Amgen (AMGN) Up 5.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
by Zacks Equity Research
BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
by Zacks Equity Research
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
by Zacks Equity Research
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
by Kinjel Shah
BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Do Options Traders Know Something About Biogen (BIIB) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Biogen (BIIB) stock based on the movements in the options market lately.
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
by Zacks Equity Research
Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.
Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?
by Kinjel Shah
Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.